ArticleAnnals of translational medicine2020
Asiaticoside attenuates neonatal hypoxic-ischemic brain damage through inhibiting TLR4/NF-κB/STAT3 pathway.
Article in Annals of translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 29 citations in OpenAlex.
- Review of neuroprotective potential of natural products against hypoxia-induced neuronal injury.Frontiers in pharmacology · 2026Review
- Neuroimmune responses in neonatal hypoxic-ischemic encephalopathy: cellular roles, crosstalk, and therapeutic opportunities.Frontiers in pediatrics · 2026Review
- Ferroptosis in Neonatal Hypoxic-Ischemic Encephalopathy: Mechanisms and the Therapeutic Potential of Vitamin D/VDR Signaling.Cellular and molecular neurobiology · 2025Review
- Metabolomic analysis suggests thiamine monophosphate as a potential marker for mesenchymal stem cell transplantation outcomes in patients with SLE.Lupus science & medicine · 2025Article
- Role of damage-associated molecular patterns in the pathogenesis and therapeutics of traumatic brain injury.Burns & trauma · 2025Review
- Asiaticoside Attenuates Blood-Spinal Cord Barrier Disruption by Inhibiting Endoplasmic Reticulum Stress in Pericytes After Spinal Cord Injury.Molecular neurobiology · 2024Article
- Farrerol Alleviates Hypoxic-Ischemic Encephalopathy by Inhibiting Ferroptosis in Neonatal Rats via the Nrf2 Pathway.Physiological research · 2023Article
- Article
- Therapeutic properties and pharmacological activities of asiaticoside and madecassoside: A review.Journal of cellular and molecular medicine · 2023Review
- The Role of the Interleukin-1 Family in Complications of Prematurity.International journal of molecular sciences · 2023Review
- Identification of Lipocalin 2 as a Ferroptosis-Related Key Gene Associated with Hypoxic-Ischemic Brain Damage via STAT3/NF-κB Signaling Pathway.Antioxidants (Basel, Switzerland) · 2023Article
- Network pharmacology and molecular docking analysis reveals the mechanism of asiaticoside on COVID-19.Annals of translational medicine · 2022Article
- Article
- Diverse Roles for Hyaluronan and Hyaluronan Receptors in the Developing and Adult Nervous System.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeonatal hypoxic ischemic encephalopathy (HIE) is currently a leading cause of neonatal death. Asiaticoside (AT), a bioactive constituent isolated from
methodsRice-Vannucci was applied to construct a hypoxic-ischemic brain damage (HIBD) model. Pathological damage of brain neuron tissue was determined by hematoxylin-eosin (HE) staining, while apoptosis was evaluated by terminal-deoxynucleoitidyl transferase nick end labeling (TUNEL) staining. Western blot and immunohistochemistry were applied to monitor related proteins levels. Enzyme-linked immunosorbent assay (ELISA) was conducted to measure the expression levels of inflammatory cytokines.
resultsThe present study indicated that AT dose-dependently ameliorated histologic damage and inhibited apoptosis induced by hypoxic ischemia (HI) (P<0.01). AT also dose-dependently alleviated oxidative damage and reduced the levels of proinflammatory cytokines (ICAM-1, IL-18, and IL-1β) and TLR4 level. In terms of mechanism, decrease of TLR and IL-18 suppressed NF-κB phosphorylation and reduced the levels of TNFα, IL-6, and p-STAT3, leading to the inactivation of NF-κB/STAT3 pathway. Interestingly, with the addition of lipopolysaccharide (LPS), the increase of TLR4 activated NF-κB/STAT3 pathway again.
conclusionsCollectively, the data provide insight into a novel mechanism by which AT may be an effective agent for HIE via the TLR4/NF-κB/STAT3 pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.